Musculoskeletal and central pain at 1 year post-stroke: associated factors and impact on quality of life

Choi-Kwon, Smi; Choi, Sun-Hye; Suh, Min Hee; Choi, Se Hyun; Cho, K.-H.; Nah, Hyun Wook; Song, H.; Kim, J. S.

doi:10.1111/ane.12617

Cited by 40 publications

(42 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical implication of this is that stroke specialists should consider CPSP as a symptom that can manifest not only in the acute and subacute phase of stroke. Our recommendation is that clinicians should look for any evidence of central neuropathic pain for at least 12 months after stroke as addressing this disabling symptom might improve patients’ quality of life [ 26 , 27 , 37 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis

et al. 2020

View full text Add to dashboard Cite

Introduction: Central post-stroke pain (CPSP) is defined as the neuropathic pain that arises either acutely or in the chronic phase of a cerebrovascular event and is a result of central lesions of the somatosensory tract. The aim of this systematic review and meta-analysis was to establish the prevalence of CPSP, to describe its characteristics, and to discuss the associated management challenges. Methods: After a systematic Medline search, we identified 69 papers eligible to be included. Results: The pooled prevalence of CPSP in patients with stroke at any location was 11% (95% CI 7-18%), which can increase to more than 50% in the subgroups of patients with medullary or thalamic strokes. CPSP onset coincides with stroke occurrence in 26% of patients (95% CI 18-35%); CPSP manifests within a month since symptom onset in 31% of patients (95% CI 22-42%), and occurs between the first month and the first year in 41% of patients (95% CI 33.9-49.0%). CPSP develops more than 12 months after stroke onset in 5% of patients (95% CI 3-8%). Conclusions: Clinicians should look for any evidence of central neuropathic pain for at least 12 months after stroke. Both pharmacological and non-pharmacological interventions can be used for the management of CPSP. Lamotrigine has the strongest evidence (Level II of evidence, derived from small randomized controlled trials) for being effective in the management of CPSP. Future research should focus on well-designed trials of pharmacological and non-pharmacological interventions aiming to relief CPSP, which is a very common but often neglected pain syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…66 Although fatigue, pain, and depression are related conditions, poststroke pain seems to be more closely associated with fatigue than depression. 52,69 Pain may somehow be involved in the persistence of fatigue over time. 26 …”

Section: Painmentioning

confidence: 99%

Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association

Hinkle¹,

Becker²,

Kim³

et al. 2017

Stroke

139

129

View full text Add to dashboard Cite

At least half of all stroke survivors experience fatigue; thus, it is a common cause of concern for patients, caregivers, and clinicians after stroke. This scientific statement provides an international perspective on the emerging evidence surrounding the incidence, prevalence, quality of life, and complex pathogenesis of poststroke fatigue. Evidence for pharmacological and nonpharmacological interventions for management are reviewed, as well as the effects of poststroke fatigue on both stroke survivors and caregivers.

show abstract

“…Other conditions often experienced by CPSP patients are sleep disorders, decreased fitness, and mood. 17 A study suggests that patients with neuropathic pain will experience disruption in mental aspects. This condition has the potential to degrade the quality of life, especially regarding mood, relations with others, and enjoyment of life.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain

Rahajeng¹,

Ikawati²,

Andayani³

et al. 2018

JYP

View full text Add to dashboard Cite

Musculoskeletal and central pain at 1 year post-stroke: associated factors and impact on quality of life

Cited by 40 publications

References 28 publications

Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis

Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis

Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association

The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain

Contact Info

Product

Resources

About